Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women

Journal of Women's Health and Gender-Based Medicine

Volumn 11, Issue 1, 2002, Pages 69-78

  Kritz Silverstein, Donna ^a   Goodman Gruen, Deborah L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; CORTICOSTEROID; DAIDZEIN; ESTROGEN; GENISTEIN; GLYCITEIN; IPRIFLAVONE; ISOFLAVONE; PHYTOESTROGEN; PLACEBO; PYRIDINIUM DERIVATIVE; RALOXIFENE; SOYBEAN PROTEIN; TAMOXIFEN; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE;

ADULT; AGE; AGED; ARTICLE; BEHAVIOR; BIOASSAY; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DIET SUPPLEMENTATION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; LIFESTYLE; LUMBAR SPINE; MAJOR CLINICAL STUDY; OBESITY; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTECTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOYBEAN; STANDARDIZATION; UNITED STATES; OSSIFICATION;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; COLLAGEN; COLLAGEN TYPE I; DIET; DOUBLE-BLIND METHOD; FEMALE; GENISTEIN; HUMANS; ISOFLAVONES; MIDDLE AGED; OSTEOGENESIS; PEPTIDES; POSTMENOPAUSE; REFERENCE VALUES;

EID: 0036191299     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/152460902753473480     Document Type: Article

References (70)

1. Isoflavones: Source and metabolism
2. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens
3. Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones
4. Oestrogenic potency of genistein and daidzin in mice
5. Naturally occurring oestrogens in foods-A review
6. Western diet and Western diseases: Some hormonal and biochemical mechanisms and associations
7. How to reduce the risk factors of osteoporosis in Asia
8. Hip fracture rates in Hong Kong and the United States, 1988 through 1989
9. Effect of ipriflavone administration on bone mass and metabolism in ovariectomized women
10. Ipriflavone prevents bone loss in postmenopausal women
11. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass
12. Effect of ipriflavone-a synthetic derivative of natural isoflavones-on bone mass loss in the early years after menopause
13. A double-blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss
14. Effect of ipriflavone on bone mass and calcuim metabolism in postmenopausal osteoporosis
15. Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial. Ipriflavone Multicenter European Fracture Study
16. Effects of dietary phytoestrogens in postmenopausal women
17. Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women
18. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women
19. Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density
20. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism
21. The bone remodeling transient: Implications for the interpretation of clinical studies of bone mass change
22. Interpreting trials of bone active agents
23. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women
24. Dietary soybean intake and bone mineral density among 995 middle-aged women in Yokohama
25. Phytooestrogen excretion and rate of bone loss in postmenopausal women
26. A data-based approach to diet questionnaire design and testing
27. Validation of a self-administered diet history questionnaire using multiple diet records
28. Phytoestrogen content of foods-A compendium of literature values
29. Anthropometric standardization reference manual
30. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density
31. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer
32. The effect of soy protein on bone metabolism
33. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study
34. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation
35. Soy phytoestrogens and bone
36. Dietary flour supplementation decreases post-menopausal hot flushes: Effect of soy and wheat
37. The role of dietary phytoestrogens in reducing cardiovascular and osteoporotic risk factors in normal postmenopausal women. Research fellowship update report
38. The role of isoflavones in menopausal health: Consensus opinion of the North American Menopause Society
39. Calcium, estrogen and progestin in the treatment of osteoporosis
40. Factors associated with appendicular bone mass in older women
41. Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial
42. Do estrogens improve bone mass in osteoporotic women over ten years of menopause
43. Estrogen replacement therapy and fractures in older women
44. The short-term effects of conjugated estrogen on bone turnover in older women
45. Postmenopausal estrogen replacement: A long-term cohort study
46. Continuous combined oestrogen/progestin therapy is well tolerated and increased bone density at the hip and spine in postmenopausal osteoporosis
47. Osteoporosis: Screening, prevention and management
48. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause
49. Postmenopausal estrogens in prevention of treatment of osteoporosis
50. Compliance with hormone therapy
51. Compliance with hormone replacement therapy. Are women receiving the full impact of hormone replacement therapy's preventive health benefits?
52. Estrogen replacement therapy. A survey of older womens attitudes
53. Why menopausal women do not want to take hormone replacement therapy
54. Postmenopausal hormone therapy: Factors influencing women's decision making
55. Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women
56. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats
57. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats
58. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis
59. Preventive effects of the plant isoflavones daidzin and genistin on bone loss in ovariectomized rats fed a calcium-deficient diet
60. Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency
61. The effect of ipriflavone and (TC-80) on bone resorption in tissue culture
62. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line
63. Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats
64. Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats
65. Effect of ipriflavone on osteoporosis induced by ovariectomy in rats
66. Effects of ipriflavone on bone and mineral metabolism in the streptozotocin diabetic rat
67. Early menopause, number of reproductive years, and bone mineral density in postmenopausal women
68. Grip strength and bone mineral density in older women